Alkem Laboratories FY24 Annual Earnings Summary

Q2 gross margin benefited from favorable U.S. product mix, which may not persist in coming quarters, potentially pressuring margins.

Despite being one of two approved generics, supply chain issues persist due to FDA-dependent secondary API source; no near-term resolution.

Pen G prices remain elevated at $28-30 vs pre-COVID $8-10; any further increase or delayed normalization could hurt gross margins.

Q4 historically weak due to seasonality and high anti-infective exposure, which could pressure margins.

Analyst questioned rationale for US facility given past St. Louis closure and competitive biosimilar landscape; management acknowledged learnings but remains confident.

Tax holidays for Sikkim facility end in FY26, potentially raising effective tax rate from 10-12% to 20-25%.

Q4 domestic decline was partly due to a weak anti-infective season; if FY25 monsoon is poor, acute portfolio growth may underperform.

While API prices are stable, any black swan event could increase costs; Pen G price decline has not materialized as expected.

Q4 had INR 30 crore in service-level penalties due to supply issues; if not resolved, could impact US margins.

India acute business underperformed due to delayed monsoons; recovery depends on seasonality and may not sustain.

Rising freight costs due to Red Sea disruptions could impact export margins; management sees manageable impact unless spike worsens.

Baddi site received 10 observations from US FDA; though management downplayed, any escalation could delay approvals.